- Home
- DMAC vs NPWR Comparison
DMAC vs NPWR Comparison
Compare DMAC & NPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- NPWR
- Stock Information
- Founded
- DMAC 2000
- NPWR 2010
- Country
- DMAC United States
- NPWR United States
- Employees
- DMAC N/A
- NPWR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- NPWR Industrial Machinery/Components
- Sector
- DMAC Health Care
- NPWR Energy
- Exchange
- DMAC Nasdaq
- NPWR Nasdaq
- Market Cap
- DMAC 260.0M
- NPWR 148.7M
- IPO Year
- DMAC N/A
- NPWR N/A
- Fundamental
- Price
- DMAC $4.45
- NPWR $3.04
- Analyst Decision
- DMAC Strong Buy
- NPWR Buy
- Analyst Count
- DMAC 4
- NPWR 2
- Target Price
- DMAC $10.75
- NPWR $4.00
- AVG Volume (30 Days)
- DMAC 393.5K
- NPWR 2.0M
- Earning Date
- DMAC 08-06-2025
- NPWR 08-11-2025
- Dividend Yield
- DMAC N/A
- NPWR N/A
- EPS Growth
- DMAC N/A
- NPWR N/A
- EPS
- DMAC N/A
- NPWR N/A
- Revenue
- DMAC N/A
- NPWR $250,000.00
- Revenue This Year
- DMAC N/A
- NPWR $308.00
- Revenue Next Year
- DMAC N/A
- NPWR $1,811.08
- P/E Ratio
- DMAC N/A
- NPWR N/A
- Revenue Growth
- DMAC N/A
- NPWR 100.00
- 52 Week Low
- DMAC $3.19
- NPWR $1.48
- 52 Week High
- DMAC $6.82
- NPWR $14.28
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- NPWR 57.88
- Support Level
- DMAC $4.81
- NPWR $2.68
- Resistance Level
- DMAC $5.60
- NPWR $2.91
- Average True Range (ATR)
- DMAC 0.49
- NPWR 0.27
- MACD
- DMAC 0.05
- NPWR -0.03
- Stochastic Oscillator
- DMAC 43.21
- NPWR 48.19
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.